The group of accredited research in Hematology and Hemotherapy of the Institute of Health Research of the University Hospital and Politècnic La Fe has identified a new genetic alteration involved in acute leukemia that will advance the knowledge of the disease, as reported by the Government in a statement .

Dr. Esperanza Such has explained that this is a unique translocation of the RARG gene in a patient with acute myeloid leukemia, who presented characteristics similar to those of patients with acute promyelocytic leukemia.

The clinical picture of the patient was remarkably similar to acute promyelocytic leukemia (APL), which is characterized by a molecular alteration consisting of rearrangement of PML genes with RARA. It is a therapeutic target for him Retinoic acid, which makes this disease one of the leukemias with the highest cure rate. However, the study of the alterations that this patient presented in their chromosomes, allowed the research group to identify a new anomaly that, in this case, affected the RARG gene.

"The identification of this gene leaves an open way to better understand the molecular mechanisms that give rise to leukemia"

It is the first time that this gene appears involved in a case of acute leukemia. It is a gene from the same family as RARA, with which it shares 90% of its sequence, and on which it had been speculated about its potential involvement in human leukemia. Thanks to this research, the patient was given the standard treatment protocol for acute leukemia.

"The identification of this gene leaves an open way to better understand the molecular mechanisms that give rise to leukemia," says Dr. José Cervera. Several European groups have echoed this finding and have requested material from the Hematology research group in order to continue in the line of work already started.

Source: EUROPE PRESS

The AML genome(s): Mutations in four dimensions (November 2019).